

## References

1. Bahamondes L1, Valeria Bahamondes M2, Shulman LP. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. *Hum Reprod Update*. 2015.
2. Eisenberg DL, Schreiber CA, Turok DK. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. 2015.
3. Vinogradova Y, Coupland C2, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. *BMJ*. 2015; 350:h2135.
4. Curtis K. U.S. selected practice recommendations for contraceptive use, 2016; 65(4):1-67.
5. Steyn P. Participatory approaches involving community and healthcare providers in family planning/contraceptive information and service provision: a scoping review. *Reproductive Health*. 2016; 13(88):1-13.
6. Centers for Disease Control and Prevention (CDC). U.S. selected practice recommendations for contraceptive use, *MMWR Recomm. Rep: Morb Mortal Wkly Rep*. 2016; 65(4):1-66.
7. Sundaram A, Vaughan B, Kost K, et al. Contraceptive Failure in the United States: Estimates from the 2006-2010 National Survey of Family Growth. *Perspect Sex Reprod Health*. 2017; 49(1):7-16.
8. Frederiksen BN, Ahrens KA, Moskosky S, Gavin L. Does Contraceptive Use in the United States Meet Global Goals? *Perspect Sex Reprod Health*. 2017; 49(4):197-205.
9. Higgins JA. Pregnancy Ambivalence and Long-Acting Reversible Contraceptive (LARC) Use among Young Adult Women: A Qualitative Study. *Perspect Sex Reprod Health*. 2017; 49(3):149-156.
10. S. Food & Drug Administration (FDA). Birth Control Guide. 2019. Accessed on March 11, 2020.

11. Ali M, Folz R, Farron M. Expanding choice and access in contraception: an assessment of intrauterine contraception policies in low and middle-income countries. *BMC Public Health*. 2019; 19(1):1-6.
12. Philliber A, Hirsch H, Brindis C, Turner R, Philliber S. The use of ACOG guidelines: Perceived contraindications to IUD and implant use among family planning providers. *Matern Child Health J*. 2017; 21(9):1706-1712.
13. de Medeiros SF. Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome. *Reprod Biol Endocrinol*. 2017; 15:1-17.
14. Jensen JT, Schlaff W, Gordon K. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. *Fertil Steril*. 2018; 110(1):137-152.e1.